Biological characterization of L-asparginase liposomal formulations

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 4, 1996, Pages 373-377

  Gaspar, M M ^a   Perez Soler, R ^b   Cruz, M E M ^a  

^a INETI   (Portugal)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

In vivo tests; L ASNase; Leukemia; Liposoma L ASNase; Liposomes; Therapeutic system

Indexed keywords

ASPARAGINASE; LIPOSOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG FORMULATION; LEUKEMIA; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG CARRIERS; LIPOSOMES; LYMPHOMA; MALE; MICE; MICE, INBRED STRAINS;

EID: 0029683047     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050497     Document Type: Article

References (20)

1. Allen TM (1989) Stealth liposomes: avoiding reticuloendothelial uptake. In: Lopez-Berestein G, Fidler I (eds) Liposomes in the therapy of infectious diseases and cancer. (New series, vol 89) Alan R. Liss, New York, pp 405-415
2. Allen TM (1994) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev 13 : 285-309
3. Allen TM, Hansen C, Rutledge J (1989) Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981 : 27-35
4. Broome JD (1961) Evidence that L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 191 : 1114-1115
5. Cruz MEM, Gaspar MM, Lopes F, Jorge JS, Perez-Soler R (1993) Liposomal L-asparaginase: in vitro evaluation. Int J Pharm 96 : 67-77
6. Fiske CH, Subbarow Y (1925) The colorimetric determination of phosphorus. J Biol Chem 66 : 375-400
7. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85 : 6949-6953
8. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH (1986) Clinical pharmacology of polyethylene glycol - L-asparaginase. Drug Metab Dispos 14 : 349-352
9. Jayaram HN, Cooney DA, Jayaram S (1974) A simple and rapid method for the estimation of L-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods. Anal Biochem 59 : 327-346
10. Jorge JCS, Perez-Soler R, Morais JG. Cruz MEM (1994) Liposomal palmitoyl-L-asparaginase: characterization and biological activity. Cancer Chemother Pharmacol 34 : 230-234
11. King EJ (1932) The colorimetric determination of phosphorus. Biochem J 26 : 292-297
12. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE (1972) Toxicity of L-asparaginase in children with advanced leukemia. Cancer 30 : 339-347
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193 : 265-275
14. MacEwen GE, Rosenthal RC, Fox LE, Loar AS, Kurzman ID (1992) Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. J Vet Intern Med 6 : 230-234
15. Mashburn LT, Wriston JC Jr (1964) Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 105 : 450-452
16. Neerunjun D, Gregoriadis G (1976) Tumor regression with liposome-entrapped asparaginase: some immunological advantages. Bichem Soc Trans 133-134
17. Oettgen HF, Phyllis AS, Morton KS, Leeper RD, Tallal L, Charlotte CT, Clarkson BD, Golbey RD, Krakoff IH, Karnopsky DA, Murphy M, Burchenal JH (1970) Toxicity of E. coli L-asparaginase in man. Cancer 25 : 253-278
18. Park YS, Maruyama K, Huang L (1992) Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. Biochim Biophys Acta 1108 : 257-260
19. Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carrier Syst 3 : 123-193
20. Wang CH, Smith RL (1975) Lowry determination of the protein in the presence of Triton X-100. Anal Biochem 63 : 414-417